Roth Upgrades Alkermes (ALKS) to Buy
More News related to ALKS
- Alkermes (ALKS) Regains Full Commercial Rights to VIVITROL(R) in US; Updates FY09 Outlook
- Alkermes Regains Full Commercialization Rights to VIVITROL(R) in US
- Alkermes' Corporate Presentation to be Webcast at JPMorgan SMid Cap Conference
- Alkermes' Corporate Presentation to be Webcast at the NASDAQ Investor Program
- Alkermes Presents Positive Preclinical Data on Novel, Proprietary Molecule Designed to Improve Outcomes for Patients Taking Opioid Analgesics
More News related to Upgrades
- BMO Upgrades Spectrum Brands (SPC) to Market Perform
- Maxim Upgrades Palomar Medical (PMTI) to Buy
- RBC Capital Upgrades DSP Group (DSPG) to Sector Perform
- UBS Upgrades Morgans Hotel Group (MHGC) to Buy
- Janney Montgomery Scott Upgrades Wright Express Corp (WXS) to Buy.
Roth Capital upgrades Alkermes (Nasdaq: ALKS) from Hold to Buy.
Alkermes, Inc., a biotechnology company, develops, and manufactures extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction, and diabetes.
Related Categories
UpgradesStocks Mentioned
+0.25Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
